Anika Therapeutics reported $17.33M in Cost of Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbott ABT:US $ 4947M 547M
Acorda Therapeutics ACOR:US $ 11.32M 0.64M
Adamas Pharmaceuticals ADMS:US 527K 142K
Agenus AGEN:US $ 667K 438K
Anika Therapeutics ANIK:US $ 17.33M 4.01M
Clovis Oncology CLVS:US $ 9.64M 0.03M
Flexion Therapeutics FLXN:US $ 4.98M 1.11M
Halozyme Therapeutics HALO:US $ 23.02M 4.8M
Heron Therapeutics HRTX:US $ 14.52M 5.32M
Insmed INSM:US $ 10.84M 993K
Integra Lifesciences IART:US $ 140.54M 4.9M
Intrexon XON:US $ 15.03M 2.06M
Johnson & Johnson JNJ:US $ 7587M 551M
Karyopharm Therapeutics KPTI:US $ 1.14M 205K
Ligand Pharmaceuticals LGND:US $ 30.59M 22.44M
MacroGenics MGNX:US 22K 5K
Merit Medical Systems MMSI:US $ 156.19M 19.17M
Peregrine Pharmaceuticals PPHM:US $ 19.36M 0.1M
Rigel Pharmaceuticals RIGL:US $ 0.13M 0.19M
Stryker SYK:US $ 1582M 60M
Surmodics SRDX:US $ 5.11M 0.94M
Veracyte VCYT:US $ 17.47M 5.07M
Zimmer Biomet Holdings Inc ZBH:US $ 581.6M 65.2M